Apixaban Use in Valvular Atrial Fibrillation
Introduction to Valvular Atrial Fibrillation
- The American College of Cardiology defines valvular AF as atrial fibrillation with moderate-to-severe mitral stenosis or mechanical heart valves, which are absolute contraindications for apixaban use 1, 2
- The American College of Cardiology recommends apixaban for patients with other forms of valvular heart disease, including mild mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation, and bioprosthetic valves 1, 2, 3
Absolute Contraindications for Apixaban
- The American Heart Association states that apixaban must not be used in patients with mechanical heart valves, due to excessive thrombotic complications and increased major bleeding 3, 4
- The American College of Cardiology recommends warfarin with target INR 2.0-3.0 for patients with moderate-to-severe mitral stenosis, which is a common condition in rheumatic heart disease 3, 4
When Apixaban Can Be Used
- The European Society of Cardiology suggests that apixaban is appropriate for AF patients with aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, and mild mitral stenosis 1, 2
- The American College of Cardiology recommends apixaban for patients with bioprosthetic valves, at least 3 months post-implantation, as an equitable alternative to warfarin 5, 6, 3
Clinical Algorithm for Decision-Making
- The American Heart Association recommends identifying the type of valve pathology and assessing valve type to determine the appropriate anticoagulant therapy, with apixaban being acceptable for bioprosthetic valves ≥3 months post-implantation 3, 5, 3
- The American College of Cardiology suggests calculating the CHA₂DS₂-VASc score to assess stroke risk and checking creatinine clearance for dosing adjustments 1, 2, 6